Valeant Pharmaceuticals International, Inc.
VRX
position
short
Marc Cohodes
Thesis
Valeant Pharmaceuticals is viewed as a potential zero by some investors due to its aggressive financial engineering and reliance on acquisitions. The company has a high likelihood of facing bankruptcy, similar to past experiences with other heavily leveraged firms.
Did it work?
inconclusive
confidence: low
Without specific price performance data or a defined time frame since the pitch, it's difficult to assess whether the thesis has played out. The thesis suggests a high likelihood of bankruptcy, but without evidence of Valeant's financial status or stock performance, we cannot determine the outcome. Therefore, the confidence in this assessment is low.
Raw excerpt
No raw excerpt stored.